EGFRVIII, His&Avi, Human
EGFRVIII, His&Avi, Human

Immobilized EGFRVIII, His & Avi, Human at 1 μg/ml (100 μl/well) on the plate. Dose response curve for Anti-EGFRVIII Antibody, hFc Tag with the EC50 of 9.2 ng/ml determined by ELISA.

EGFRVIII, His&Avi, Human

EGFRVIII, His & Avi, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

EGFRVIII, His&Avi, Human

The purity of EGFRVIII, His & Avi, Human is greater than 95% as determined by SEC-HPLC.

EGFRVIII, His&Avi, Human

The epidermal growth factor receptor (EGFR) is overexpressed in a variety of human epithelial tumors, often as a consequence of gene amplification. Tumors with EGFR gene amplification frequently contain EGFR gene rearrangements, with the most common extracellular domain mutation being EGFRvIII. This mutation leads to a deletion of exons 2-7 of the EGFR gene and renders the mutant receptor incapable of binding any known ligand.
Z03940
¥67,155.00

Ask us a question
Product Introduction
Species Human
Protein Construction
Avi His EGFRVIII (Leu25-Ser378)
Accession # NP_001333870.1
N-term C-term
Purity > 95% as determined by Bis-Tris PAGE
> 95% as determined by HPLC
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Immobilized EGFRVIII, His&Avi, Human (Cat.No.: Z03940) at 1 μg/ml (100μl/Well) on the plate can bind Anti-EGFRVIII Antibody, hFc Tag.
Expression System HEK293
Theoretical Molecular Weight 41.6 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 68-80 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from a 0.22 μm filtered solution in PBS, (pH 7.4).
Reconstitution It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH2O more than 100 μg/ml.
Storage & Stability Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

Examples
  • EGFRVIII, His&Avi, Human
    • EGFRVIII, His&Avi, Human

    Immobilized EGFRVIII, His & Avi, Human at 1 μg/ml (100 μl/well) on the plate. Dose response curve for Anti-EGFRVIII Antibody, hFc Tag with the EC50 of 9.2 ng/ml determined by ELISA.

  • EGFRVIII, His&Avi, Human
    • EGFRVIII, His&Avi, Human

    EGFRVIII, His & Avi, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

  • EGFRVIII, His&Avi, Human
    • EGFRVIII, His&Avi, Human

    The purity of EGFRVIII, His & Avi, Human is greater than 95% as determined by SEC-HPLC.


Background
Target Background Epidermal growth factor receptor (EGFR) is a transmembrane protein. It can be activated by epidermal growth factor or transforming growth factor alpha (TGF-α). EGFR plays an important role in cell survival, proliferation and angiogenesis. EGFR is highly expressed in a variety of solid tumours. It is a common target for cancer therapy.
Synonyms ErbB; EC 2.7.10; EC 2.7.10.1; EGFR; mENA; LEGFR; ERBB; ERBB1; HER1; PIG61; NISBD2

For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.